Morning all,
Thought I'd start a new thread and mention many eyes are on AHZ today - with the early approval (not expected until June) of Cardiocel by the FDA.
PYC continues to creep up on expectations of a deal cut by Janssen in the near future.
Focus has shifted somewhat from RHT in the last few weeks as the traders exit from it's recent stella run - stabilising around 7 cents.
What does the week hold for other BIO's?
